ID   KCNN2_RAT               Reviewed;         580 AA.
AC   P70604;
DT   16-NOV-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   02-OCT-2024, entry version 179.
DE   RecName: Full=Small conductance calcium-activated potassium channel protein 2 {ECO:0000305};
DE            Short=SK2;
DE            Short=SKCa 2;
DE            Short=SKCa2;
DE   AltName: Full=KCa2.2;
GN   Name=Kcnn2 {ECO:0000312|RGD:2963};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY
RP   REGULATION, AND TISSUE SPECIFICITY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=8781233; DOI=10.1126/science.273.5282.1709;
RA   Koehler M., Hirschberg B., Bond C.T., Kinzie J.M., Marrion N.V., Maylie J.,
RA   Adelman J.P.;
RT   "Small-conductance, calcium-activated potassium channels from mammalian
RT   brain.";
RL   Science 273:1709-1714(1996).
RN   [2]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND INTERACTION WITH CALMODULIN.
RX   PubMed=9774106; DOI=10.1038/26758;
RA   Xia X.M., Fakler B., Rivard A.F., Wayman G., Johnson-Pais T., Keen J.E.,
RA   Ishii T., Hirschberg B., Bond C.T., Lutsenko S., Maylie J., Adelman J.P.;
RT   "Mechanism of calcium gating in small-conductance calcium-activated
RT   potassium channels.";
RL   Nature 395:503-507(1998).
RN   [3]
RP   FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=11325723; DOI=10.1016/s0006-3495(01)76193-0;
RA   Soh H., Park C.S.;
RT   "Inwardly rectifying current-voltage relationship of small-conductance
RT   Ca2+-activated K+ channels rendered by intracellular divalent cation
RT   blockade.";
RL   Biophys. J. 80:2207-2215(2001).
RN   [4]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-161, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16641100; DOI=10.1073/pnas.0600895103;
RA   Hoffert J.D., Pisitkun T., Wang G., Shen R.-F., Knepper M.A.;
RT   "Quantitative phosphoproteomics of vasopressin-sensitive renal cells:
RT   regulation of aquaporin-2 phosphorylation at two sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7159-7164(2006).
RN   [5]
RP   FUNCTION, TRANSPORTER ACTIVITY, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   HIS-337; ASN-345 AND ASN-368.
RX   PubMed=20562108; DOI=10.1074/jbc.m110.110072;
RA   Lamy C., Goodchild S.J., Weatherall K.L., Jane D.E., Liegeois J.F.,
RA   Seutin V., Marrion N.V.;
RT   "Allosteric block of KCa2 channels by apamin.";
RL   J. Biol. Chem. 285:27067-27077(2010).
RN   [6]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF ARG-396; LYS-397 AND
RP   GLU-399.
RX   PubMed=21422289; DOI=10.1073/pnas.1103090108;
RA   Li W., Aldrich R.W.;
RT   "Electrostatic influences of charged inner pore residues on the conductance
RT   and gating of small conductance Ca2+ activated K+ channels.";
RL   Proc. Natl. Acad. Sci. U.S.A. 108:5946-5953(2011).
RN   [7] {ECO:0007744|PDB:1G4Y}
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 395-490 IN COMPLEX WITH
RP   CALMODULIN, FUNCTION, DOMAIN, AND SUBUNIT.
RX   PubMed=11323678; DOI=10.1038/35074145;
RA   Schumacher M.A., Rivard A.F., Bachinger H.P., Adelman J.P.;
RT   "Structure of the gating domain of a Ca2+-activated K+ channel complexed
RT   with Ca2+/calmodulin.";
RL   Nature 410:1120-1124(2001).
CC   -!- FUNCTION: Small conductance calcium-activated potassium channel that
CC       mediates the voltage-independent transmembrane transfer of potassium
CC       across the cell membrane through a constitutive interaction with
CC       calmodulin which binds the intracellular calcium allowing its opening
CC       (PubMed:11325723, PubMed:20562108, PubMed:21422289, PubMed:8781233,
CC       PubMed:9774106). The current is characterized by a voltage-independent
CC       activation, an intracellular calcium concentration increase-dependent
CC       activation and a single-channel conductance of about 3 picosiemens
CC       (PubMed:8781233, PubMed:9774106). Also presents an inwardly rectifying
CC       current, thus reducing its already small outward conductance of
CC       potassium ions, which is particularly the case when the membrane
CC       potential displays positive values, above + 20 mV (PubMed:8781233,
CC       PubMed:9774106). The inward rectification could be due to a blockade of
CC       the outward current by intracellular divalent cations such as calcium
CC       and magnesium and could also be due to an intrinsic property of the
CC       channel pore, independent of intracellular divalent ions
CC       (PubMed:11325723, PubMed:21422289). There are three positively charged
CC       amino acids in the S6 transmembrane domain, close to the pore, that
CC       collectively control the conductance and rectification through an
CC       electrostatic mechanism (PubMed:21422289). Additionally, electrostatic
CC       contributions from these residues also play an important role in
CC       determining the intrinsic open probability of the channel in the
CC       absence of calcium, affecting the apparent calcium affinity for
CC       activation (PubMed:21422289). Forms an heteromeric complex with
CC       calmodulin, which is constitutively associated in a calcium-independent
CC       manner (PubMed:9774106). Channel opening is triggered when calcium
CC       binds the calmodulin resulting in a rotary movement leading to the
CC       formation of the dimeric complex to open the gate (PubMed:11323678,
CC       PubMed:9774106). Plays a role in the repolarization phase of cardiac
CC       action potential (By similarity). {ECO:0000250|UniProtKB:Q9H2S1,
CC       ECO:0000269|PubMed:11323678, ECO:0000269|PubMed:11325723,
CC       ECO:0000269|PubMed:20562108, ECO:0000269|PubMed:21422289,
CC       ECO:0000269|PubMed:8781233, ECO:0000269|PubMed:9774106}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=K(+)(in) = K(+)(out); Xref=Rhea:RHEA:29463, ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000269|PubMed:11325723, ECO:0000269|PubMed:20562108,
CC         ECO:0000269|PubMed:21422289, ECO:0000269|PubMed:8781233,
CC         ECO:0000269|PubMed:9774106};
CC   -!- ACTIVITY REGULATION: Inhibited by bee venom neurotoxin apamin
CC       (PubMed:20562108, PubMed:8781233). Inhibited by UCL 1684 and
CC       tetraethylammonium (TEA) (PubMed:20562108).
CC       {ECO:0000269|PubMed:20562108, ECO:0000269|PubMed:8781233}.
CC   -!- SUBUNIT: Homodimer (By similarity). Heteromultimer with KCNN1 and KCNN3
CC       (By similarity). The complex is composed of 4 channel subunits each of
CC       which binds to a calmodulin subunit which regulates the channel
CC       activity through calcium-binding (PubMed:11323678, PubMed:9774106).
CC       Interacts (via N-terminal domain) with MPP2 (By similarity).
CC       {ECO:0000250|UniProtKB:P58390, ECO:0000269|PubMed:11323678,
CC       ECO:0000269|PubMed:9774106}.
CC   -!- INTERACTION:
CC       P70604; P0DP29: Calm3; NbExp=6; IntAct=EBI-1031103, EBI-397530;
CC   -!- SUBCELLULAR LOCATION: Membrane {ECO:0000255}; Multi-pass membrane
CC       protein {ECO:0000255}. Cytoplasm, myofibril, sarcomere, Z line
CC       {ECO:0000250|UniProtKB:P58390}.
CC   -!- TISSUE SPECIFICITY: Brain. {ECO:0000269|PubMed:8781233}.
CC   -!- DOMAIN: The calmodulin-binding domain (CaMBD) forms an elongated dimer
CC       with a calmodulin molecule bound at each end; each calmodulin wraps
CC       around three alpha-helices, two from one CaMBD subunit and one from the
CC       other. {ECO:0000269|PubMed:11323678}.
CC   -!- DOMAIN: The coiled-coil domaim mediates heteromeic assembly.
CC       {ECO:0000250|UniProtKB:Q9H2S1}.
CC   -!- SIMILARITY: Belongs to the potassium channel KCNN family. KCa2.2/KCNN2
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U69882; AAB09563.1; -; mRNA.
DR   RefSeq; NP_062187.1; NM_019314.2.
DR   PDB; 1G4Y; X-ray; 1.60 A; B=396-487.
DR   PDB; 1KKD; NMR; -; A=396-487.
DR   PDB; 1QX7; X-ray; 3.09 A; D=411-487.
DR   PDB; 2PNV; X-ray; 2.10 A; A/B=488-526.
DR   PDB; 3SJQ; X-ray; 1.90 A; C/D=412-487.
DR   PDB; 4G27; X-ray; 1.65 A; B=396-487.
DR   PDB; 4G28; X-ray; 1.63 A; B=396-487.
DR   PDB; 4J9Y; X-ray; 1.51 A; B=396-487.
DR   PDB; 4J9Z; X-ray; 1.66 A; B=396-487.
DR   PDB; 4QNH; X-ray; 2.02 A; B=396-487.
DR   PDB; 6CZQ; X-ray; 2.20 A; B=395-487.
DR   PDBsum; 1G4Y; -.
DR   PDBsum; 1KKD; -.
DR   PDBsum; 1QX7; -.
DR   PDBsum; 2PNV; -.
DR   PDBsum; 3SJQ; -.
DR   PDBsum; 4G27; -.
DR   PDBsum; 4G28; -.
DR   PDBsum; 4J9Y; -.
DR   PDBsum; 4J9Z; -.
DR   PDBsum; 4QNH; -.
DR   PDBsum; 6CZQ; -.
DR   AlphaFoldDB; P70604; -.
DR   BMRB; P70604; -.
DR   SMR; P70604; -.
DR   DIP; DIP-35337N; -.
DR   IntAct; P70604; 1.
DR   MINT; P70604; -.
DR   STRING; 10116.ENSRNOP00000060708; -.
DR   BindingDB; P70604; -.
DR   ChEMBL; CHEMBL2547; -.
DR   DrugCentral; P70604; -.
DR   GuidetoPHARMACOLOGY; 382; -.
DR   iPTMnet; P70604; -.
DR   PhosphoSitePlus; P70604; -.
DR   jPOST; P70604; -.
DR   PaxDb; 10116-ENSRNOP00000060708; -.
DR   ABCD; P70604; 1 sequenced antibody.
DR   GeneID; 54262; -.
DR   KEGG; rno:54262; -.
DR   UCSC; RGD:2963; rat.
DR   AGR; RGD:2963; -.
DR   CTD; 3781; -.
DR   RGD; 2963; Kcnn2.
DR   VEuPathDB; HostDB:ENSRNOG00000016675; -.
DR   eggNOG; KOG3684; Eukaryota.
DR   HOGENOM; CLU_014617_0_1_1; -.
DR   InParanoid; P70604; -.
DR   PhylomeDB; P70604; -.
DR   TreeFam; TF315015; -.
DR   Reactome; R-RNO-1296052; Ca2+ activated K+ channels.
DR   EvolutionaryTrace; P70604; -.
DR   PRO; PR:P70604; -.
DR   Proteomes; UP000002494; Chromosome 18.
DR   Bgee; ENSRNOG00000016675; Expressed in frontal cortex and 15 other cell types or tissues.
DR   ExpressionAtlas; P70604; baseline and differential.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0043197; C:dendritic spine; IDA:RGD.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0045211; C:postsynaptic membrane; ISO:RGD.
DR   GO; GO:0042383; C:sarcolemma; ISO:RGD.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; ISO:RGD.
DR   GO; GO:0030315; C:T-tubule; ISO:RGD.
DR   GO; GO:0030018; C:Z disc; ISO:RGD.
DR   GO; GO:0051393; F:alpha-actinin binding; ISO:RGD.
DR   GO; GO:0015269; F:calcium-activated potassium channel activity; ISO:RGD.
DR   GO; GO:0005516; F:calmodulin binding; IDA:UniProtKB.
DR   GO; GO:0005242; F:inward rectifier potassium channel activity; ISO:RGD.
DR   GO; GO:0019904; F:protein domain specific binding; ISO:RGD.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0016286; F:small conductance calcium-activated potassium channel activity; IDA:UniProtKB.
DR   GO; GO:0098914; P:membrane repolarization during atrial cardiac muscle cell action potential; ISO:RGD.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0043268; P:positive regulation of potassium ion transport; IMP:RGD.
DR   GO; GO:0071805; P:potassium ion transmembrane transport; ISO:RGD.
DR   GO; GO:0006813; P:potassium ion transport; IDA:UniProtKB.
DR   GO; GO:0048168; P:regulation of neuronal synaptic plasticity; IMP:RGD.
DR   GO; GO:1901379; P:regulation of potassium ion transmembrane transport; ISO:RGD.
DR   DisProt; DP01141; -.
DR   Gene3D; 1.10.287.70; -; 2.
DR   InterPro; IPR004178; CaM-bd_dom.
DR   InterPro; IPR036122; CaM-bd_dom_sf.
DR   InterPro; IPR015449; K_chnl_Ca-activ_SK.
DR   InterPro; IPR013099; K_chnl_dom.
DR   PANTHER; PTHR10153; SMALL CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL; 1.
DR   PANTHER; PTHR10153:SF43; SMALL CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNEL PROTEIN 2; 1.
DR   Pfam; PF02888; CaMBD; 1.
DR   Pfam; PF07885; Ion_trans_2; 1.
DR   Pfam; PF03530; SK_channel; 1.
DR   PRINTS; PR01451; SKCHANNEL.
DR   SMART; SM01053; CaMBD; 1.
DR   SUPFAM; SSF81327; Small-conductance potassium channel; 1.
DR   SUPFAM; SSF81324; Voltage-gated potassium channels; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calmodulin-binding; Cytoplasm; Ion channel; Ion transport;
KW   Membrane; Phosphoprotein; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..580
FT                   /note="Small conductance calcium-activated potassium
FT                   channel protein 2"
FT                   /id="PRO_0000155012"
FT   TRANSMEM        140..160
FT                   /note="Helical; Name=Segment S1"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        169..189
FT                   /note="Helical; Name=Segment S2"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        215..235
FT                   /note="Helical; Name=Segment S3"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        257..277
FT                   /note="Helical; Name=Segment S4"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        306..326
FT                   /note="Helical; Name=Segment S5"
FT                   /evidence="ECO:0000255"
FT   INTRAMEM        346..366
FT                   /note="Pore-forming; Name=Segment H5"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        375..395
FT                   /note="Helical; Name=Segment S6"
FT                   /evidence="ECO:0000255"
FT   REGION          1..68
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          88..116
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          413..489
FT                   /note="Calmodulin-binding"
FT                   /evidence="ECO:0000269|PubMed:11323678"
FT   REGION          551..580
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        101..116
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        566..580
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         161
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:16641100"
FT   MUTAGEN         337
FT                   /note="H->N: Loss of inhibition by apamin and the organic
FT                   molecule blockers UCL 1684 and d-tubocurarine. No effect on
FT                   inhibition by tetraethylammonium (TEA)."
FT                   /evidence="ECO:0000269|PubMed:20562108"
FT   MUTAGEN         345
FT                   /note="N->G: Reduced inhibition by apamin but binding to
FT                   apamin is unaffected."
FT                   /evidence="ECO:0000269|PubMed:20562108"
FT   MUTAGEN         368
FT                   /note="N->H: Reduced inhibition by apamin but binding to
FT                   apamin is unaffected."
FT                   /evidence="ECO:0000269|PubMed:20562108"
FT   MUTAGEN         396
FT                   /note="R->E: Mostly eliminates inward rectifier potassium
FT                   channel activity. Loss of inward rectifier potassium
FT                   channel activity; when associated with E-397. Significantly
FT                   increases outward single-channel conductance at positive
FT                   potentials. Significantly increases outward single-channel
FT                   conductance at positive potentials; when associated with E-
FT                   397. Increases inward rectifier potassium channel activity.
FT                   Does not affect inward rectifier potassium channel
FT                   activity; when associated with R-399. Decreases inward
FT                   rectifier potassium channel activity; when associated with
FT                   E-397 and R-399. Significantly increases apparent calcium
FT                   affinity. Five-fold increases in the apparent calcium
FT                   affinity; when associated with E.397. Highly increases
FT                   apparent calcium affinity; when associated with E-397 and
FT                   R-399."
FT                   /evidence="ECO:0000269|PubMed:21422289"
FT   MUTAGEN         396
FT                   /note="R->K: Does not affect inward rectifier potassium
FT                   channel activity. Does not affect apparent calcium
FT                   affinity."
FT                   /evidence="ECO:0000269|PubMed:21422289"
FT   MUTAGEN         396
FT                   /note="R->N: Highly decreases inward rectifier potassium
FT                   channel activity; when associated with N-397. Slightly
FT                   decreases apparent calcium affinity."
FT                   /evidence="ECO:0000269|PubMed:21422289"
FT   MUTAGEN         397
FT                   /note="K->E: Moderately reduces inward rectifier potassium
FT                   channel activity. Loss of inward rectifier potassium
FT                   channel activity; when associated with E-396. Significantly
FT                   increases outward single-channel conductance at positive
FT                   potentials; when associated with E-396. Decreases inward
FT                   rectifier potassium channel activity; when associated with
FT                   E-396 and R-399. Highly increases apparent calcium
FT                   affinity; when associated with E-396 and R-399."
FT                   /evidence="ECO:0000269|PubMed:21422289"
FT   MUTAGEN         397
FT                   /note="K->N: Highly decreases inward rectifier potassium
FT                   channel activity; when associated with N-396."
FT                   /evidence="ECO:0000269|PubMed:21422289"
FT   MUTAGEN         399
FT                   /note="E->R: Increases inward rectifier potassium channel
FT                   activity. Does not affect inward rectifier potassium
FT                   channel activity; when associated with E-396. Decreases
FT                   inward rectifier potassium channel activity; when
FT                   associated with E-396 and E-397.Highly increases apparent
FT                   calcium affinity; when associated with E-396 and E-397."
FT                   /evidence="ECO:0000269|PubMed:21422289"
FT   STRAND          398..401
FT                   /evidence="ECO:0007829|PDB:1KKD"
FT   HELIX           414..439
FT                   /evidence="ECO:0007829|PDB:4J9Y"
FT   STRAND          440..443
FT                   /evidence="ECO:0007829|PDB:6CZQ"
FT   HELIX           446..485
FT                   /evidence="ECO:0007829|PDB:4J9Y"
FT   HELIX           489..523
FT                   /evidence="ECO:0007829|PDB:2PNV"
SQ   SEQUENCE   580 AA;  63848 MW;  F71E0DAF7EEFA8D4 CRC64;
     MSSCRYNGGV MRPLSNLSSS RRNLHEMDSE AQPLQPPASV VGGGGGASSP SAAAAASSSA
     PEIVVSKPEH NNSNNLALYG TGGGGSTGGG GGGGGGGGGS GHGSSSGTKS SKKKNQNIGY
     KLGHRRALFE KRKRLSDYAL IFGMFGIVVM VIETELSWGA YDKASLYSLA LKCLISLSTI
     ILLGLIIVYH AREIQLFMVD NGADDWRIAM TYERIFFICL EILVCAIHPI PGNYTFTWTA
     RLAFSYAPST TTADVDIILS IPMFLRLYLI ARVMLLHSKL FTDASSRSIG ALNKINFNTR
     FVMKTLMTIC PGTVLLVFSI SLWIIAAWTV RACERYHDQQ DVTSNFLGAM WLISITFLSI
     GYGDMVPNTY CGKGVCLLTG IMGAGCTALV VAVVARKLEL TKAEKHVHNF MMDTQLTKRV
     KNAAANVLRE TWLIYKNTKL VKKIDHAKVR KHQRKFLQAI HQLRSVKMEQ RKLNDQANTL
     VDLAKTQNIM YDMISDLNER SEDFEKRIVT LETKLETLIG SIHALPGLIS QTIRQQQRDF
     IETQMENYDK HVTYNAERSR SSSRRRRSSS TAPPTSSESS
//
